Why Medicus Pharma Ltd.’s (MDCX) Stock Is Down 12.50%
As of Monday, October 27, Medicus Pharma Ltd.’s MDCX share price has dipped by 12.50%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin. The company has a strategic collaboration with the Gorlin Syndrome Alliance to access to SKINJECT in Patients with Gorlin Syndrome. The company was formerly known as Interactive Capital Partners Corporation and changed its name to Medicus Pharma Ltd. in September 2023. The company was incorporated in 2008 and is headquartered in West Conshohocken, Pennsylvania.
Commentary & Analysis
Why Medicus Pharma Ltd.’s (MDCX) Stock Is Down 5.59%
As of Monday, October 13, Medicus Pharma Ltd.’s MDCX share price has dipped by 5.59%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Medicus Pharma Ltd.’s (MDCX) Stock Is Up 5.58%
As of Friday, October 10, Medicus Pharma Ltd.’s MDCX share price has surged by 5.58%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Medicus Pharma Ltd.’s (MDCX) Stock Is Down 6.08%
As of Monday, September 29, Medicus Pharma Ltd.’s MDCX share price has dipped by 6.08%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Medicus Pharma Ltd.’s (MDCX) Stock Is Down 5.26%
As of Wednesday, September 24, Medicus Pharma Ltd.’s MDCX share price has dipped by 5.26%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | MDCX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $16.4 | $288.9 | 9% |
|
| Shares Out (Mil) | 55.1 | 54.0 | 50% |
|
| Institutional Ownership | 65.3% | 93.1% | 40% |
|
| Float (Mil) | 59.8 | 41.4 | 51% |
|
| Beta | -0.48 | 0.94 | 2% |
|
| Avg Daily Volume (000s) | 819 | 480 | 68% |
|
| Price Change (52-week) |
(87.5%) | 59.9% | 5% |
|
| Growth | MDCX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 15.9% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | MDCX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($57) | ($43) | 15% |
|
| EPS (TTM) | ($1.660) | ($1.500) | 16% |
|
| Operating Cash Flow (TTM) (Mil) | ($29) | ($31) | 13% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $18 | $4 | 32% |
|
| Enterprise Value (Q1) (Mil) | $23 | $190 | 12% |
|
| Valuation | MDCX | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.84 | na |
|
| P/E | na | 20.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | MDCX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (74.2%) | na |
|
| ROA | (290.2%) | (47.7%) | 1% |
|
| ROE | na | (55.0%) | na |
|
| Liabilities to Assets | 106.4% | 29.6% | 95% |
|
| F-Score | 2 | 3 | 7% |
|
Medicus Pharma Ltd. did not pass any screens on 9/2/2026.
